

SCIENTIFIC PROGRAM

As at March 7, 2004

MONDAY, MAY 10, 2004

Session I: ADVANCES IN THE PATHOPHYSIOLOGY OF DRUG RESISTANCE

Chairpersons: **E. Abadie**, France
R. Katz, USA

PHARMACORESISTANCE AS A DISORDER OF TRANSPORT SYSTEMS
S.M. Sisodiya, University College London, London, UK

ALTERED ION CHANNELS AND PHARMACORESISTANCE
M. Baulac, Pitié-Salpêtrière Hospital, Paris, France

PREDICTING PHARMACORESISTANCE
M.J. Brodie, Western Infirmary, Glasgow, UK

CAN WE MODEL EXISTING RCT DATA TO PREDICT OUTCOME OF TREATMENT VS NO TREATMENT IN NEWLY DIAGNOSED EPILEPSY? PROPOSAL FOR A PROJECT
J.A. French, University of Pennsylvania, Philadelphia, USA

DOES EPILEPSY BECOME RESISTANT?
G. Avanzini, C. Besta Neurological Institute, Milan, Italy

Session II: MODES OF AED ACTION AND SPECTRUM OF ADVERSE EFFECTS

Chairpersons: **G. Avanzini**, Italy
S.C. Schachter, USA

SODIUM CHANNEL BLOCKERS
I.E. Leppik, University of Minnesota, Minneapolis, USA

GABA-ERGIC DRUGS
R. Kälviäinen, Kuopio University Hospital, Finland

POTASSIUM CHANNEL BLOCKERS AND CARBONIC ANHYDRASE INHIBITORS
B. Bourgeois, Harvard Medical School, Boston, USA

Session III: UPDATE ON PHARMACOGENOMICS

Chairpersons: **G. Avanzini**, Italy
S.C. Schachter, USA

GENETIC ASSOCIATION STUDIES IN EPILEPSY PHARMACOGENOMICS, WHAT HAVE WE LEARNT AND WHAT IS THEIR POTENTIAL?
S. Shorvon, University College London, London, UK

TUESDAY, MAY 11, 2004

Session IV - A: DRUGS IN DEVELOPMENT

Chairpersons: **M. Bialer**, Israel
R.H. Levy, USA

FLUOROFELBAMATE
B.A. Roecklein, *MedPointe Healthcare, Inc*, USA

PREGABALIN
Pfizer, USA
Presented by **J.A. French**, University of Pennsylvania, Philadelphia, USA

RETIGABINE (D-23129)
Speaker to be announced

SAFINAMIDE
Newron Pharmaceuticals, Italy
Presented by **E. Perucca**, University of Pavia, Pavia, Italy

STIRIPENTOL
Laboratoires Biocodex, France
Presented by **C. Chiron**, Saint Vincent de Paul Hospital, Paris, France

TALAMPANEL
N. Bodor, *IVAX Corporation*, USA

Session IV – B: DRUGS IN DEVELOPMENT

Chairpersons: **V. Biton**, USA
H.J. Kupferberg, USA

VALROCEMIDE (TV1901)
Teva, Israel
Presented by **M. Bialer**, Hebrew University of Jerusalem, Israel

BIA 2-093
P. Soares-da-Silva, *BIAL*, Portugal

RWJ –333369
D.G.A. Kasteleijn-Nolst Trenité, Medical Center Alkmaar, The Netherlands

SPM 927
P. Doty, *Schwarz BioSciences*, USA

NPS 1776
L.D. Artman, *NPS Pharmaceuticals*, USA

ALPHA-2 ANTAGONISM AND EPILEPTOGENESIS
Orion Pharma Finland
Presented by **A. Pitkänen**, University of Kuopio, Finland

WEDNESDAY, MAY 12, 2004

Session V - A: PROGRESS REPORT ON RECENTLY MARKETED DRUGS

Chairpersons: **E. Perucca**, Italy
T. Tomson, Sweden

FELBAMATE
Speaker to be announced

GABAPENTIN
B. Parsons, *Pfizer Inc.*, New York, USA

LAMOTRIGINE
Presented by **V. Biton**, Arkansas Epilepsy Program, Little Rock, Arkansas, USA

LEVETIRACETAM
P. Verdru, *UCB S.A.*, Belgium

OXCARBAZEPINE
Novartis, Switzerland
Presented by **S.C. Schachter**, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Boston, USA

Session V - B: PROGRESS REPORT ON RECENTLY MARKETED DRUGS

Chairpersons: **I.E. Leppik**, USA
M.Y. Neufeld, Israel

TIAGABINE
Cephalon Ltd., UK
Presented by **R. Kälviäinen**, Kuopio University Hospital, Finland

TOPIRAMATE
S. Schwabe, *Johnson & Johnson Pharmaceutical Research & Development.*, USA

VIGABATRIN
M. Baulac, Pitié-Salpêtrière Hospital, Paris, France (**waiting for confirmation**)

ZONISAMIDE
Elan Pharmaceuticals, USA
Presented by **R.E. Ramsay**, University of Miami Medical School, Miami, USA

PHARMACOKINETICS AND CLINICAL EXPERIENCE WITH DEPAKOTE ER
Abbott Laboratories, USA
Presented by **J.C. Cloyd**, Epilepsy Research & Education Program, College of Pharmacy, Minneapolis, USA

NEW FORMULATIONS OF VALPROATE
Sanofi-Synthelabo, France
Presented by **O. Dulac**, Hopital Saint Vincent de Paul, Paris, France

RECENT CLINICAL TRIALS OF IV FORMULATIONS IN EPILEPSY
K.W. Sommerville, *Schwarz Biosciences*, USA

VAGUS NERVE STIMULATION
Cyberonics, USA

Presented by **S.C. Schachter**, Beth Israel Deaconess Medical Center, Harvard Clinical
Research Institute, Boston, USA

WEDNESDAY, MAY 12, 2004

Session VI - NEW AEDs IN PEDIATRIC EPILEPSY SYNDROMES

Chairpersons: **B. Bourgeois, USA**
 F. Vigevano, Italy

NEW AEDs IN PARTIAL EPILEPSY OF CHILDHOOD; RANDOMIZED TRIALS VS
GENERAL CLINICAL EXPERIENCE
A. Arzimanoglou, Robert Debré Hospital, Paris, France

THURSDAY, MAY 13, 2004

Session VI (continued) - NEW AEDs IN PEDIATRIC EPILEPSY SYNDROMES

Chairpersons: **B. Bourgeois**, USA
 F. Vigevano, Italy

NEW AEDs IN GENERALIZED EPILEPSY SYNDROMES
F. Vigevano, Pediatric Hospital Bambino Gesù, Rome, Italy

EXTRAPOLATING FROM ADULT TRIALS TO THE PEDIATRIC POPULATION:
REGULATORY PERSPECTIVE
R. Katz, FDA, Rockville, USA

EXTRAPOLATING FROM ADULT TRIALS TO THE PEDIATRIC POPULATION: CLINICAL
PERSPECTIVE
C. Chiron, Saint Vincent de Paul Hospital, Paris, France

**Session VII: A RE-APPRAISAL OF COMPARATIVE RESPONSES TO AED
COMBINATIONS**

Chairpersons: **S. Johannessen**, Norway
 R. Kälviäinen, Finland

EVALUATING AED COMBINATIONS IN EXPERIMENTAL MODELS:
METHODOLOGICAL ASPECTS
S. White, University of Utah, Salt Lake City, USA

COMPARING ANTICONVULSANT ACTIVITY AND NEUROTOXICITY IN ANIMAL MODELS:
WHY ARE SOME AED COMBINATIONS SUPERIOR TO OTHERS?
S.J. Czuczwar, Medical University, Lublin, Poland

CLINICALLY FAVORABLE AED COMBINATIONS
B. Schmidt, Wittnau, Germany

CLINICALLY ADVERSE AED COMBINATIONS
T. Tomson, Karolinska Hospital, Stockholm, Sweden